Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma

Blocking autophagy with hydroxychloroquine (HCQ) augments cell death associated with alkylating chemotherapy in preclinical models. This phase I study evaluated the maximum tolerated dose (MTD), safety, preliminary activity, pharmacokinetics, and pharmacodynamics of HCQ in combination with dose-inte...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Rangwala, Reshma, Leone, Robert, Chang, Yunyoung C, Fecher, Leslie A, Schuchter, Lynn M, Kramer, Amy, Tan, Kay-See, Heitjan, Daniel F, Rodgers, Glenda, Gallagher, Maryann, Piao, Shengfu, Troxel, Andrea B, Evans, Tracey L, DeMichele, Angela M, Nathanson, Katherine L, O’Dwyer, Peter J, Kaiser, Jonathon, Pontiggia, Laura, Davis, Lisa E, Amaravadi, Ravi K
Formato: Artigo
Idioma:Inglês
Publicado: Landes Bioscience 2014
Assuntos:
Clinical Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4203514/
https://ncbi.nlm.nih.gov/pubmed/24991839
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/auto.29118
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares